LOS ANGELES--(BUSINESS WIRE)--Avantogen Oncology, Inc. (OTCBB:AVTO) today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration for RP101, a compound being investigated for the treatment of patients with pancreatic cancer.
